Edition:
United Kingdom

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

56.36USD
23 Feb 2018
Change (% chg)

$-0.04 (-0.07%)
Prev Close
$56.40
Open
$56.54
Day's High
$56.88
Day's Low
$55.61
Volume
191,181
Avg. Vol
451,088
52-wk High
$86.21
52-wk Low
$42.63

Chart for

About

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The... (more)

Overall

Beta: 0.22
Market Cap(Mil.): $4,132.42
Shares Outstanding(Mil.): 86.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.60
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-DexCom Says Preliminary Q4 Revenue Was $218 Mln

* DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK

08 Jan 2018

BRIEF-Dexcom announces development agreement with Lilly

* Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem

21 Nov 2017

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

01 Nov 2017

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

24 Oct 2017

BRIEF-‍Janus Henderson reports 10.2 pct passive stake in Dexcom

* ‍Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing​ Source text: (http://bit.ly/2ybb4kH) Further company coverage:

11 Oct 2017

BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes

* ‍Fitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes​

07 Sep 2017

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

28 Aug 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Johnson & Johnson (JNJ.N) $132.02 +2.11
Abbott Laboratories (ABT.N) $59.71 +0.72
Medtronic PLC (MDT.N) $80.39 -0.02

Earnings vs. Estimates